Report Detail

Request for Sample of this report

Pharma & Healthcare Global Eptacog Alfa (rFVIIa) Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

  • RnM4529380
    • |
  • 20 April, 2023
    • |
  • Global
    • |
  • 94 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
According to our (Global Info Research) latest study, the global Eptacog Alfa (rFVIIa) market size was valued at USD 1224.5 million in 2022 and is forecast to a readjusted size of USD 1655.4 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
This report is a detailed and comprehensive analysis for global Eptacog Alfa (rFVIIa) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Eptacog Alfa (rFVIIa) market size and forecasts, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2018-2029
Global Eptacog Alfa (rFVIIa) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2018-2029
Global Eptacog Alfa (rFVIIa) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2018-2029
Global Eptacog Alfa (rFVIIa) market shares of main players, shipments in revenue ($ Million), sales quantity (g), and ASP (US$/mg), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Eptacog Alfa (rFVIIa)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Eptacog Alfa (rFVIIa) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, LFB SA, GENERIUM, Northland-bio and CSL, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Eptacog Alfa (rFVIIa) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Freeze-dried Preparation
Freeze-dried Powder
Market segment by Application
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Major players covered
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Eptacog Alfa (rFVIIa) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Eptacog Alfa (rFVIIa), with price, sales, revenue and global market share of Eptacog Alfa (rFVIIa) from 2018 to 2023.
Chapter 3, the Eptacog Alfa (rFVIIa) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Eptacog Alfa (rFVIIa) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Eptacog Alfa (rFVIIa) market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Eptacog Alfa (rFVIIa).
Chapter 14 and 15, to describe Eptacog Alfa (rFVIIa) sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Eptacog Alfa (rFVIIa)
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Eptacog Alfa (rFVIIa) Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Freeze-dried Preparation
    • 1.3.3 Freeze-dried Powder
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Eptacog Alfa (rFVIIa) Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hemophilia
    • 1.4.3 Acquired Hemophilia
    • 1.4.4 Factor VII Deficiency
    • 1.4.5 Glanzmann Thrombasthenia (GT)
  • 1.5 Global Eptacog Alfa (rFVIIa) Market Size & Forecast
    • 1.5.1 Global Eptacog Alfa (rFVIIa) Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Eptacog Alfa (rFVIIa) Sales Quantity (2018-2029)
    • 1.5.3 Global Eptacog Alfa (rFVIIa) Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk
    • 2.1.1 Novo Nordisk Details
    • 2.1.2 Novo Nordisk Major Business
    • 2.1.3 Novo Nordisk Eptacog Alfa (rFVIIa) Product and Services
    • 2.1.4 Novo Nordisk Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Novo Nordisk Recent Developments/Updates
  • 2.2 LFB SA
    • 2.2.1 LFB SA Details
    • 2.2.2 LFB SA Major Business
    • 2.2.3 LFB SA Eptacog Alfa (rFVIIa) Product and Services
    • 2.2.4 LFB SA Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 LFB SA Recent Developments/Updates
  • 2.3 GENERIUM
    • 2.3.1 GENERIUM Details
    • 2.3.2 GENERIUM Major Business
    • 2.3.3 GENERIUM Eptacog Alfa (rFVIIa) Product and Services
    • 2.3.4 GENERIUM Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 GENERIUM Recent Developments/Updates
  • 2.4 Northland-bio
    • 2.4.1 Northland-bio Details
    • 2.4.2 Northland-bio Major Business
    • 2.4.3 Northland-bio Eptacog Alfa (rFVIIa) Product and Services
    • 2.4.4 Northland-bio Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Northland-bio Recent Developments/Updates
  • 2.5 CSL
    • 2.5.1 CSL Details
    • 2.5.2 CSL Major Business
    • 2.5.3 CSL Eptacog Alfa (rFVIIa) Product and Services
    • 2.5.4 CSL Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 CSL Recent Developments/Updates
  • 2.6 Shire (Takeda)
    • 2.6.1 Shire (Takeda) Details
    • 2.6.2 Shire (Takeda) Major Business
    • 2.6.3 Shire (Takeda) Eptacog Alfa (rFVIIa) Product and Services
    • 2.6.4 Shire (Takeda) Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Shire (Takeda) Recent Developments/Updates
  • 2.7 Bayer
    • 2.7.1 Bayer Details
    • 2.7.2 Bayer Major Business
    • 2.7.3 Bayer Eptacog Alfa (rFVIIa) Product and Services
    • 2.7.4 Bayer Eptacog Alfa (rFVIIa) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Bayer Recent Developments/Updates

3 Competitive Environment: Eptacog Alfa (rFVIIa) by Manufacturer

  • 3.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Eptacog Alfa (rFVIIa) Revenue by Manufacturer (2018-2023)
  • 3.3 Global Eptacog Alfa (rFVIIa) Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Eptacog Alfa (rFVIIa) by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Eptacog Alfa (rFVIIa) Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Eptacog Alfa (rFVIIa) Manufacturer Market Share in 2022
  • 3.5 Eptacog Alfa (rFVIIa) Market: Overall Company Footprint Analysis
    • 3.5.1 Eptacog Alfa (rFVIIa) Market: Region Footprint
    • 3.5.2 Eptacog Alfa (rFVIIa) Market: Company Product Type Footprint
    • 3.5.3 Eptacog Alfa (rFVIIa) Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Eptacog Alfa (rFVIIa) Market Size by Region
    • 4.1.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Region (2018-2029)
    • 4.1.3 Global Eptacog Alfa (rFVIIa) Average Price by Region (2018-2029)
  • 4.2 North America Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
  • 4.3 Europe Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
  • 4.5 South America Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Eptacog Alfa (rFVIIa) Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
  • 5.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Type (2018-2029)
  • 5.3 Global Eptacog Alfa (rFVIIa) Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
  • 6.2 Global Eptacog Alfa (rFVIIa) Consumption Value by Application (2018-2029)
  • 6.3 Global Eptacog Alfa (rFVIIa) Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
  • 7.2 North America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
  • 7.3 North America Eptacog Alfa (rFVIIa) Market Size by Country
    • 7.3.1 North America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
  • 8.2 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
  • 8.3 Europe Eptacog Alfa (rFVIIa) Market Size by Country
    • 8.3.1 Europe Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Eptacog Alfa (rFVIIa) Market Size by Region
    • 9.3.1 Asia-Pacific Eptacog Alfa (rFVIIa) Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Eptacog Alfa (rFVIIa) Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
  • 10.2 South America Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
  • 10.3 South America Eptacog Alfa (rFVIIa) Market Size by Country
    • 10.3.1 South America Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Eptacog Alfa (rFVIIa) Market Size by Country
    • 11.3.1 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Eptacog Alfa (rFVIIa) Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Eptacog Alfa (rFVIIa) Market Drivers
  • 12.2 Eptacog Alfa (rFVIIa) Market Restraints
  • 12.3 Eptacog Alfa (rFVIIa) Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Eptacog Alfa (rFVIIa) and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Eptacog Alfa (rFVIIa)
  • 13.3 Eptacog Alfa (rFVIIa) Production Process
  • 13.4 Eptacog Alfa (rFVIIa) Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Eptacog Alfa (rFVIIa) Typical Distributors
  • 14.3 Eptacog Alfa (rFVIIa) Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Eptacog Alfa (rFVIIa). Industry analysis & Market Report on Eptacog Alfa (rFVIIa) is a syndicated market report, published as Global Eptacog Alfa (rFVIIa) Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Eptacog Alfa (rFVIIa) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,784.00
    		4,176.00
    		5,568.00
    		3,239.88
    		4,859.82
    		6,479.76
    		540,826.80
    		811,240.20
    		1,081,653.60
    		290,580.00
    		435,870.00
    		581,160.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo